Article

Dynamic ctDNA tracking stratifies individual relapse risk for early triple negative breast cancer patients receiving neoadjuvant chemotherapy

2024-07-10

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold> Early Triple negative breast cancer (eTNBC) is the breast cancer subtype with the least favorable outcome. Tools to identify their individual relapse risk are in great need. Circulating tumor DNA (ctDNA) analysis is shown to predict the prognosis in breast cancer, but its utility in eTNBC remains unclear.<bold>Patients and methods</bold> In this prospective study...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c9fa8d41-3d35-5cab-8039-f395d8486875
DOI: 10.21203/rs.3.rs-4480804/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dynamic ctDNA tracking stratifies individual relapse risk for early triple negative breast cancer patients receiving neoadjuvant chemotherapyDOI 10.21203/rs.3.rs-4480804/v1Read

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read

Dynamic Analysis of Circulating Tumor DNA to Predict the Prognosis and Monitor the Treatment Response of Patients with Metastatic Triple-negative Breast Cancer: a prospective studySemantic proximity Read

Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.Semantic proximity Read

Circulating tumor DNA as a predictive marker of recurrence for patients with stage II-III breast cancer treated with neoadjuvant therapySemantic proximity Read

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.Semantic proximity Read

Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity Read

Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapySemantic proximity Read

Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.Semantic proximity Read

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Semantic proximity Read

Breast cancer: Tracking ctDNA to evaluate relapse risk.Semantic proximity Read

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survivalSemantic proximity Read

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Semantic proximity Read